Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined
with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of …

Coronary artery disease (CAD), including stable angina and acute coronary syndrome
(ACS), is a leading cause of death and hospitalization in Canada. 1 About 2.4 million adult …

Introduction 'Real world'bleeding in patients exposed to different regimens of dual
antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) have a …

The use of antiplatelet monotherapy as part of treatment regimens for high-risk patients with
thrombotic disease results in significant reductions in ischaemic outcomes. Numerous …

Long-term dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) is recommended after acute coronary syndrome (ACS) to reduce the …

Risk-based antithrombotic strategies after percutaneous coronary intervention (PCI). Dual
antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is indicated for …

Introduction Early dual antiplatelet therapy (DAPT) discontinuation was shown to
significantly increase morbidity and mortality in acute coronary syndromes. Our objectives …

Dual antiplatelet therapy (DAPT) is a class I guideline indication after percutaneous
coronary intervention (PCI). Our population is high-risk for low medication adherence. With a …

International guidelines recommend the use of aspirin treatment immediately and
indefinitely in coronary patients. The optimal time to start and the duration of dual antiplatelet …

Coronary artery disease (CAD) is prevalent throughout the world, with a significant impact
on global health. There is a vast collection of data in the medical literature relating to the …